0.96
Matinas Biopharma Holdings Inc stock is traded at $0.96, with a volume of 22,358.
It is up +1.05% in the last 24 hours and down -0.43% over the past month.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.
See More
Previous Close:
$0.95
Open:
$0.959
24h Volume:
22,358
Relative Volume:
0.09
Market Cap:
$4.88M
Revenue:
-
Net Income/Loss:
$-21.13M
P/E Ratio:
-0.2004
EPS:
-4.79
Net Cash Flow:
$-16.95M
1W Performance:
+0.00%
1M Performance:
-0.43%
6M Performance:
+57.38%
1Y Performance:
+466.71%
Matinas Biopharma Holdings Inc Stock (MTNB) Company Profile
Name
Matinas Biopharma Holdings Inc
Sector
Industry
Phone
908-443-1860
Address
1545 Route 206 South, Suite 302, Bedminster, NJ
Compare MTNB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MTNB
Matinas Biopharma Holdings Inc
|
0.9599 | 4.83M | 0 | -21.13M | -16.95M | -4.79 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.48 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
326.68 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.58 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.76 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Matinas Biopharma Holdings Inc Stock (MTNB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Aug-26-20 | Resumed | Piper Sandler | Overweight |
Jan-27-20 | Initiated | Piper Sandler | Overweight |
Jan-24-20 | Initiated | SunTrust | Buy |
Jan-23-20 | Initiated | SunTrust | Buy |
Jan-09-20 | Initiated | Aegis Capital | Buy |
Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Matinas Biopharma Holdings Inc Stock (MTNB) Latest News
What analysts say about Matinas BioPharma Holdings Inc. stockExceptional market positioning - Autocar Professional
Is Matinas BioPharma Holdings Inc. a good long term investmentBreakthrough profit margins - Autocar Professional
What analysts say about HASI stockFree Investment Timing Strategies - jammulinksnews.com
How Matinas BioPharma Holdings Inc. stock performs during market volatilitySmart Return Focused Trading - Newser
Matinas BioPharma Holdings Inc. Stock Analysis and ForecastBreakout profit opportunities - jammulinksnews.com
What drives Matinas BioPharma Holdings Inc. stock priceFree Stock Market Mentorship - jammulinksnews.com
Is Renovaro Inc. a good long term investmentSuperior capital gains - jammulinksnews.com
What makes Matinas BioPharma Holdings Inc. stock price move sharplyShort Squeeze Radar - beatles.ru
What analysts say about WRAP stockOutstanding capital returns - jammulinksnews.com
Why Matinas BioPharma Holdings Inc. stock attracts strong analyst attentionQuick Profit Idea Stream - Newser
Why Hayward Holdings Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - Newser
Aspergillosis Pipeline 2025: FDA Updates, Therapy - openPR.com
Diversification Wins: Global ETFs Shine in First Half of 2025 - The Globe and Mail
Matinas BioPharma Approves 2025 Equity Incentive Plan - TipRanks
MTNB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Pre-market Movers: HCTI, KLTO, INTS, HSDT... - RTTNews
Kalkine Matinas BioPharma Surges Amid NYSE Composite Market Momentum - Kalkine Media
Matinas Biopharma (NYSE:MTNB) Trading 5.7% Higher – Here’s Why - Defense World
Matinas Biopharma (NYSE:MTNB) versus Marker Therapeutics (NASDAQ:MRKR) Head to Head Review - Defense World
Matinas BioPharma amends bylaws, updates on officer agreements By Investing.com - Investing.com Canada
Matinas BioPharma Amends Bylaws and Sets Annual Meeting - TipRanks
Matinas BioPharma amends bylaws, updates on officer agreements - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Matinas Biopharma (NYSE:MTNB) Shares Down 2.6% – Here’s What Happened - Defense World
MTNB stock touches 52-week low at $0.48 amid sharp annual decline - Investing.com Australia
MTNB stock touches 52-week low at $0.48 amid sharp annual decline By Investing.com - Investing.com South Africa
Matinas Biopharma Holdings Inc Stock (MTNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):